EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder

Devi Nair, Xavier Freixa, Christopher R Ellis, Dhanunjaya Lakkireddy, Jens Erik Nielsen-Kudsk, Rodney Horton, Vivek Y Reddy, Akash Makkar, Reda Ibrahim, Himanshu Agarwal, Ole de Backer, Sajjad Sabir und 3 weitere

JACC: Clinical Electrophysiology · 2026-06 · 12 (6) · 1331-1341

DOI: 10.1016/j.jacep.2026.01.021 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026-06. Verfasst von Devi Nair und 14 weiteren Autor:innen. Beteiligte Einrichtung: St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA. Electronic address: drdevignair@gmail.com. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Left Atrial Appendage Closure, Septal Occluder Device. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Abbott Pharmaceuticals, Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Percutaneous left atrial appendage occlusion (LAAO) is an alternative stroke prevention strategy in atrial fibrillation patients deemed unsuitable to tolerate long-term oral anticoagulation. Although current LAAO devices have been shown to provide stroke protection, they have been associated with peridevice leak and pericardial effusion. The VERITAS study evaluates the safety and effectiveness of Abbott's next-generation dual-seal LAAO device. OBJECTIVES: The purpose of this study was to assess the VERITAS primary endpoints and key clinical outcomes through 45 days. METHODS: In this prospective, global, multicenter, single-arm study, atrial fibrillation patients with CHA2DS2-VASc ≥2 for men and ≥3 for women underwent LAAO with the next-generation dual-sealing device (Amulet 360). The primary safety endpoint included key adverse events through 7 days postprocedure or hospital discharge, whichever was later. The primary effectiveness endpoint was LAAO (leak ≤5 mm) by 45-day transesophageal echocardiography, assessed by an independent core laboratory. RESULTS: Across 34 global sites, 400 patients (age 73.8 ± 7.4 years, 62% men, CHA2DS2-VASc 4.1 ± 1.4, and HAS-BLED 3.1 ± 1.0) were enrolled and underwent an implant attempt. LAAO implant success was 99.8% (399 of 400). The incidence for the primary safety endpoint was 0.0% (0 of 400). All (100%) patients assessed with echocardiography met the primary effectiveness endpoint. At 45 days, complete LAAO (0 mm leak) was observed in 93.9% of patients. Two (0.5%) patients required percutaneous draining for pericardial effusions and device-related thrombus was observed in 2.4% of patients. CONCLUSIONS: The VERITAS study demonstrates high implant success of the next-generation dual-seal LAAO device, and a favorable short-term safety and sealing profile. (Abbott Medical-VERITAS Study; NCT06707688).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial AppendageAtrial FibrillationLeft Atrial Appendage ClosureSeptal Occluder DeviceAgedAged, 80 and overFemaleHumansMaleEchocardiography, TransesophagealProspective StudiesStrokeTreatment Outcome

Stichwörter der Autor:innen

amuletatrial fibrillationleft atrial appendage occlusionstroke

Autor:innen und Institutionen

  • St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA. Electronic address: drdevignair@gmail.com.
  • Hospital Clinic de Barcelona, lnstitut Clinic Cardiovascular, Barcelona, Spain.
  • Vanderbilt Heart Institute, Nashville, Tennessee, USA.
  • Kansas City Heart Rhythm Institute and Research Foundation, Overland Park, Kansas, USA.
  • Aarhus University Hospital, Aarhus N, Denmark.
  • Texas Cardiac Arrythmia, Austin, Texas, USA.

Förderung

  • Abbott Pharmaceuticals
  • Abbott Laboratories

Zitieren

APA

Nair, D., Freixa, X., Ellis, C. R., Lakkireddy, D., Nielsen-Kudsk, J. E., Horton, R., Reddy, V. Y., Makkar, A., Ibrahim, R., Agarwal, H., de Backer, O., Sabir, S., Weiler, C., Alkhouli, M., & VERITAS Investigators (2026). Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Clinical Electrophysiology, 12(6), 1331-1341. https://doi.org/10.1016/j.jacep.2026.01.021

Vancouver

Nair D, Freixa X, Ellis CR, Lakkireddy D, Nielsen-Kudsk JE, Horton R, et al. Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder. JACC: Clinical Electrophysiology. 2026;12(6):1331-1341. doi:10.1016/j.jacep.2026.01.021

BibTeX
@article{Nair2026,
  author = {Nair, Devi and Freixa, Xavier and Ellis, Christopher R and Lakkireddy, Dhanunjaya and Nielsen-Kudsk, Jens Erik and Horton, Rodney and Reddy, Vivek Y and Makkar, Akash and Ibrahim, Reda and Agarwal, Himanshu and de Backer, Ole and Sabir, Sajjad and Weiler, Courtney and Alkhouli, Mohamad and VERITAS Investigators, VERITAS Investigators},
  title = {Early Outcomes With a Next-Generation Dual-Seal Left Atrial Appendage Occluder},
  journal = {JACC: Clinical Electrophysiology},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {1331--1341},
  doi = {10.1016/j.jacep.2026.01.021}
}
Kostenlos starten →